NextCure, Inc(NASDAQ:NXTC) 
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment o...
Website: http://www.nextcure.com
IPO Price: $15 (May 08, 2019)
Full Time Employees: 69
CEO: Michael S. Richman
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 4.80
H 4.80
L 4.44
C 4.68
V 97,822
10EMA 4.68
20EMA 4.68
60EMA 4.68
120EMA 4.68
250EMA 4.68